Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers
NCT01404754 · MT-1 · Resilient Pharmaceuticals
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Profile of Mood States (POMS)
Measured over Experimental session approximately six hours after drug administration
Profile of Mood States (POMS)
Measured over Day prior to each experimental session
Profile of Mood States (POMS)
Measured over Day after each experimental session
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
3 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| Aguazul Bluewater, Inc. | Boulder | Colorado | United States |
| Santa Fe MDMA Therapy Training, LLC | Santa Fe | New Mexico | United States |
| Zen Therapeutic Solutions | Mt. Pleasant | South Carolina | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT01404754 on ClinicalTrials.gov →
Last updated in the registry 2024-10-31. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Indication
Recruiting in